Moving beyond chemotherapy: Novel cytostatic agents for malignant mesothelioma

Lung Cancer

Volumn 45, Issue SUPPL., 2004, Pages

  Kindler, Hedy L ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Epidermal growth factor; Novel cytostatic agents; Platelet derived growth factor; Tyrosine kinase; Vascular endothelial growth factor

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR; GEFITINIB; IMATINIB; PLATELET DERIVED GROWTH FACTOR; SEMAXANIB; THALIDOMIDE; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG TARGETING; ENZYME INHIBITION; HUMAN; MALIGNANT MESOTHELIOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

ANTINEOPLASTIC AGENTS; HUMANS; MESOTHELIOMA; PHTHALAZINES; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 3142731985     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.04.022     Document Type: Conference Paper

References (19)

1. Ong S.T., Vogelzang N.J. Chemotherapy in malignant pleural mesothelioma: a review. J. Clin. Oncol. 14:1996;1007-1017
2. Kindler H.L. Malignant pleural mesothelioma. Curr. Treat. Options Oncol. 1:2000;313-326
3. Ohta Y., Shridhar V., Bright R.K., Kalemkerian G.P., Du W., Carbone M., et al. VEGF, VEGF type C, and their receptors play an important role in angiogenesis and lymphangiogensis in human malignant mesothelioma tumors. Br. J. Cancer. 81:1999;54-61
4. Strizzi L., Catalano A., Vianale G., Orecchia S., Casalini A., Tassi G., et al. Vascular endothelial growth factor is an autocrine growth factor in malignant mesothelioma. J. Pathol. 193:2001;468-475
5. Linder C., Linder S., Munck-Wikland E., Strander H. Independent expression of serum vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in patients with carcinoma and sarcoma. Anticancer Res. 18:1998;2063-2068
6. Vermeulen P.B., Dirix L.Y., Martin M., DePooter C., Schrijvers D., Prove A., et al. Serum levels of b-FGF and FGF in patients with metastatic solid tumors. Proc. Am. Soc. Clin. Oncol. 15:1996;90
7. Kindler H.L., Vogelzang N.J., Chien K., Stadler W.M., Karczmar G., Heimann R., et al. SU5416 in malignant mesothelioma: a University of Chicago phase II consortium study. Proc. Am. Soc. Clin. Oncol. 20:2001;341
8. Kabbinavar F.F., Wong J.T., Ayala R.E., Wintroub A.B., Kim K.J., Ferrana N., et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc. Am. Assoc. Cancer Res. 36:1995;488
9. Kindler H.L. A double-blind placebo-controlled randomized phase II trial of gemcitabine and cisplatin with or without the VEGF inhibitor bevacizumab in patients with malignant mesothelioma. Curr. Clin. Trials Thorac. Oncol. 4:2001;2-4
10. Eisen T., Boshoff C., Mak I., Sapunar F., Vaughan M.M., Pyle L., et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian, and breast cancer. Br. J. Cancer. 82:2000;812-817
11. Govindan R., Ritter J., Suppiah R. EGFR and HER-2 overexpression in malignant mesothelioma. Proc. Am. Soc. Clin. Oncol. 20:2001;339
12. Ciardiello F., Caputo R., Bianco R., Damiano V., Pomatico G., De Placido S., et al. Antitumor effect and potentiation of cytotoxic drug activity in human cells by ZD1839 (Iressa), an epidermal growth factor selective tyrosine kinase inhibitor. Clin. Cancer Res. 6:2000;2053-2063
13. Langerak A.W., De Laat P.A., Van Der Linden-Van Beurden C.A., Delahaye M., Van Der Kwast T.H., Hoogsteden H.C., et al. Expression of platelet-derived growth factor (PDGF) and PDGF receptors in human malignant mesothelioma in vitro and in vivo. J. Pathol. 178:1996;151-160
14. Gerwin B.I., Lechner J.F., Reddel R.R., Roberts A.B., Robbins K.C., Gabrielson E.W., et al. Comparison of production of transforming growth factor-beta and platelet derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 47:1987;6180-6184
15. Mutsaers S.E., McAnulty R.J., Laurent G.J., Versnel M.A., Whitaker D., Papadimitriou J.M. Cytokine regulation of mesothelial cell proliferation in vitro and in vivo. Eur. J. Cell Biol. 72:1997;24-29
16. Versnel M.A., Claesson-Welsh L., Hammacher A., Bouts M.J., van der Kwast T.H., Eriksson A., et al. Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha receptors. Oncogene. 6:1991;2005-2011
17. Dorai T., Kobayashi H., Holland J.F., Ohnuma T. Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mol. Pharmacol. 46:1994;437-444
18. Buchdunger E., Cioffi C.L., Law N., Stover D., Ohno-Jones S., Druker B.J., et al. Abl protein tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet derived growth factor receptors. J. Pharmacol. Exp. Ther. 295:2000;139-145
19. Wood J.M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor receptor-induced responses and tumor growth after oral administration. Cancer Res. 60:2000;2178-2189